Non-Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Failed Therapy

ALK +
- EGFR/HER2 Mutation, Untreated CNS Mets
  - VAR0098 Phase I First-in-Human Dose-Escalation/Safety/Tolerability/Pharmacokinetics of X-396 in Solid Tumors
    - PI: Wakelee Xcovery
  - LUN0082 Phase III Anti-Tumor Activity of Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer
    - PI: Neil Ariad Pharmaceuticals
  - LUN0097 Phase II Regorafenib in Combo w/ Oral Methotrexate in KRAS Mutated Non-Small Cell Lung Cancer(NSCLC)
    - PI: Padda Stanford

KRAS+
- Failed EGFR or ALK Inhibitor

Failed EFGIR/ Resistant to TKI inhibitors

TK1/2nd Generation

LUN0095 Phase I AZD9791 & Necitumumab in EGFR-Mutant NSCLC After Progression on Previous EGFR TKI
  - PI: Padda NCI

TK1/3rd Generation

LUN0083 Phase I/II AC010MA Previously Treated EGFRmut & Acquired T790M Mutation Non-Small Cell Lung Cancer
  - PI: Wakelee Vanderbilt University

LUN0090 Phase I Aftatinib & Necitumumab in EGFR Mutation-NSCLC w/ 1st / 3rd Gen EGFR TKIs Acquired Resistance
  - PI: Padda Vanderbilt University

LUN0084 Phase II Rx-001 in SCLC / NSCLC / Neuroendocrine Carcinoma or Ovarian Cancer (Including MGMT)
  - PI: Padda EpicentRx, Inc

Mesothelin +
- NY ESO-1 LAGE-1a
  - CCT5017 Phase Ib/II Screening for Tumor Antigen Expression Profiling & HLA Typing in Solid & Hematological Malignancies
    - PI: Neal Adapimmune Ltd
    - Pending

VAR0155 Phase Ib Anetumab Ravtansine (BAY 94-9343) in Mesothelin Expressing Advanced/Recurrent Malignancies
  - PI: Padda Bayer

LUN0078 Phase I LAGE-1a
  - MAGE-A10

LUN0080-CCT5004 I/II MAGE-A10+766T in Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
  - PI: Neal Adapimmune Ltd

Key:
- Open for Enrollment
- Link
- Optional Path
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu